Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Nuria Martinez‐Cibrian"'
Autor:
Gloria Iacoboni, Víctor Navarro, Pierre Sesques, Kai Rejeski, Mariana Bastos-Oreiro, Fabio Serpenti, Ana Africa Martin Lopez, Josu Iraola-Truchuelo, Javier Delgado, Ariadna Perez, Manuel Guerreiro, Ana Carolina Caballero, Nuria Martinez-Cibrian, Hugo Luzardo Henriquez, Jose Maria Sanchez Pina, Juan-Manuel Sancho, Hervé Ghesquieres, Alberto Mussetti, Lucia Lopez Corral, Rafael Hernani, Juan Luis Reguera, Anna Sureda, Francesc Bosch, Alejandro Martin Garcia-Sancho, Mi Kwon, Marion Subklewe, Andrea Kuhnl, Emmanuel Bachy, Pere Barba, Guillermo Villacampa, Pau Abrisqueta
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-10 (2024)
Abstract Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are h
Externí odkaz:
https://doaj.org/article/7a33c510abd6496482324ad69e68ca9f
Autor:
Valentín Ortiz-Maldonado, Nuria Martinez-Cibrian, Marta Español-Rego, Guillermo Muñoz-Sanchez, Sergio Navarro, Leticia Alserawan, Maria Castella, Daniel Benitez-Ribas, Laura Magnano, Eva Gine, Luis Gerardo Rodríguez Lobato, Alexandra Martínez Roca, Helena Brillembourg, Mercedes Montoro, Pilar Ayora, Carlos Fernandez de Larrea, Mariona Pascal, Jordi Esteve, Avaro Urbano Ispizua, Manel Juan, Julio Delgado
Publikováno v:
HemaSphere, Vol 7, p e97357cb (2023)
Externí odkaz:
https://doaj.org/article/353b639924cd4a21aab34baf0da7e62d
Autor:
Nuria Martinez-Cibrian, Valentín Ortiz-Maldonado, Marta Español-Rego, Daniel Benitez-Ribas, Joan Cid, Miquel Lozano, Sergio Navarro, Laura Magnano, Eva Gine, Juan Gonzalo Correa Saldarriaga, Pablo Mozas, Luis Gerardo Rodríguez Lobato, Helena Brillembourg, Mercedes Montoro, Pilar Ayora, Leticia Alserawan, Alexandra Martínez Roca, Armando Lopez-Guillermo, Avaro Urbano Ispizua, Manel Juan, Mariona Pascal, Julio Delgado
Publikováno v:
HemaSphere, Vol 7, p e4838399 (2023)
Externí odkaz:
https://doaj.org/article/4cc0fa417f064bf2a92f41693b017ea0
Autor:
Nuria Martinez-Cibrian, Sergi Betriu, Valentín Ortiz-Maldonado, Daniel Esteban, Natalia Tovar, Ana Triguero Moreno, Leticia Alserawan, Mercedes Montoro, Anna Van Muyden, Maike Spoon, Margot Pont, Christian Jacques, Julio Delgado
Publikováno v:
HemaSphere, Vol 7, p e026794e (2023)
Externí odkaz:
https://doaj.org/article/7bb3c33ab7064174ba362a9b50e49254
Autor:
Nuria Martinez-Cibrian, Marta Español-Rego, Mariona Pascal, Julio Delgado, Valentín Ortiz-Maldonado
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European Union and other jurisdictions. In Spain, the 100%
Externí odkaz:
https://doaj.org/article/1b4381fb80f14eb9b8ac5d72d310c398
Autor:
Gloria Iacoboni, Guillermo Villacampa, Nuria Martinez‐Cibrian, Rebeca Bailén, Lucia Lopez Corral, Jose M. Sanchez, Manuel Guerreiro, Ana Carolina Caballero, Alberto Mussetti, Juan‐Manuel Sancho, Rafael Hernani, Pau Abrisqueta, Carlos Solano, Anna Sureda, Javier Briones, Alejandro Martin Garcia‐Sancho, Mi Kwon, Juan Luis Reguera‐Ortega, Pere Barba, GETH, GELTAMO Spanish Groups
Publikováno v:
Cancer Medicine, Vol 10, Iss 10, Pp 3214-3223 (2021)
Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results o
Externí odkaz:
https://doaj.org/article/c5750ec54d2047259016169d6fdbead9
Autor:
Tommaso-Francesco Aiello, Pedro Puerta-Alcalde, Mariana Chumbita, Carlos Lopera, Patricia Monzó, Albert Cortes, Francesc Fernández-Avilés, María Suárez-Lledó, Juan Correa, Valentín Ortiz-Maldonado, Genoveva Cuesta, Nuria Martinez-Cibrian, Jordi Esteve, Maria Ángeles Marcos, Josep Mensa, Alex Soriano, Carolina Garcia-Vidal
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:1454-1459
Objectives We aimed to describe the clinical outcomes and duration of viral shedding in high-risk patients with haematological malignancies hospitalized with COVID-19 during Omicron variant predominance who received early treatment with antivirals. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0e223ac5031a9fad211b83a1bd01a36
https://doi.org/10.1093/jac/dkad105
https://doi.org/10.1093/jac/dkad105
A national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience
Autor:
Andrea Kuhnl, Claire Roddie, Amy A. Kirkwood, Eleni Tholouli, Tobias Menne, Amit Patel, Caroline Besley, Sridhar Chaganti, Robin Sanderson, Maeve O'Reilly, Jane Norman, Wendy Osborne, Adrian Bloor, Sanne Lugthart, Ram Malladi, Piers E. M. Patten, Lorna Neill, Nuria Martinez‐Cibrian, Hannah Kennedy, Elizabeth H. Phillips, Ceri Jones, Kirsty Sharplin, Dima El‐Sharkawi, Anne‐Louise Latif, Amrith Mathew, Benjamin Uttenthal, Orla Stewart, Maria A. V. Marzolini, William Townsend, Kate Cwynarski, Kirit Ardeshna, Arzhang Ardavan, Kate Robinson, Antonio Pagliuca, Graham P. Collins, Roderick Johnson, Andrew McMillan
Publikováno v:
British Journal of Haematology. 198:492-502
CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide results of a large national
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017628ccff28172fef0cf1f897295514
https://doi.org/10.1111/bjh.18209
https://doi.org/10.1111/bjh.18209
Publikováno v:
Blood reviews. 48
Graft-versus-host disease (GvHD) was first described in 1959, since then major efforts have been made in order to understand its physiopathology and animal models have played a key role. Three steps, involving different pathways, have been recognised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a5095397a6ba52c82631787b2168da
https://pubmed.ncbi.nlm.nih.gov/33386151
https://pubmed.ncbi.nlm.nih.gov/33386151
Autor:
Gloria Iacoboni, Josu Iraola‐Truchuelo, Maeve O'Reilly, Víctor Navarro, Tobias Menne, Mi Kwon, Ana África Martín‐López, Sridhar Chaganti, Javier Delgado, Claire Roddie, Ariadna Pérez, Jane Norman, Manuel Guerreiro, Adam Gibb, Ana Carolina Caballero, Caroline Besley, Nuria Martínez‐Cibrián, Alberto Mussetti, Robin Sanderson, Hugo Luzardo, Sunil Iyengar, Jose Maria Sánchez, Ceri Jones, Juan‐Manuel Sancho, Pere Barba, Anne‐Louise Latif, Lucia López‐Corral, Rafael Hernani, Juan Luis Reguera, Anna Sureda, Alejandro Martin Garcia‐Sancho, Mariana Bastos, Pau Abrisqueta, Andrea Kuhnl
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract Over 60% of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line of therapy and information in this setting
Externí odkaz:
https://doaj.org/article/da69c64401f4489eb88ab02b2a46bb49